Datopotamab Deruxtecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Trial Timeline
Jan 8, 2024 → Jan 1, 2029
NCT ID
NCT06176261About Datopotamab Deruxtecan
Datopotamab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06176261. Target conditions include Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06279728 | Pre-clinical | Completed |
| NCT06676917 | Phase 2 | Withdrawn |
| NCT06176261 | Phase 2 | Recruiting |
| NCT05866432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Breast Cancer